Nuveen Asset Management, LLC Crinetics Pharmaceuticals, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

A detailed history of Nuveen Asset Management, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 514,194 shares of CRNX stock, worth $28.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

514,194

Previous 462,766 11.11%

Holding current value

$28.1 Million

Previous $20.7 Million 26.72%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$43.83 - $54.98 $2.25 Million - $2.83 Million	51,428 Added 11.11%	514,194 $26.3 Million
Q2 2024 Aug 09, 2024	SELL	$42.12 - $51.91 $3.83 Million - $4.72 Million	-90,973 Reduced 16.43%	462,766 $20.7 Million
Q1 2024 May 13, 2024	SELL	$34.76 - $46.81 $4.36 Million - $5.87 Million	-125,432 Reduced 18.47%	553,739 $25.9 Million
Q4 2023 Feb 14, 2024	BUY	$25.62 - $37.07 $6.87 Million - $9.94 Million	268,230 Added 65.27%	679,171 $24.2 Million
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $1.08 Million - $2.07 Million	67,762 Added 19.75%	410,941 $12.2 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $3.44 Million - $5.17 Million	218,870 Added 176.07%	343,179 $6.18 Million
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $204,909 - $282,402	-13,384 Reduced 9.72%	124,309 $2 Million
Q4 2022 Feb 14, 2023	SELL	$15.49 - $19.05 $2.46 Million - $3.03 Million	-158,898 Reduced 53.57%	137,693 $2.52 Million
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $1.91 Million - $2.36 Million	-105,419 Reduced 26.22%	296,591 $5.83 Million
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $1.73 Million - $2.9 Million	104,885 Added 35.3%	402,010 $7.5 Million
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $27,662 - $45,664	1,613 Added 0.55%	297,125 $5.65 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $3.38 Million - $4.96 Million	174,456 Added 144.11%	295,512 $7.16 Million
Q3 2021 Nov 12, 2021	SELL	$16.88 - $25.23 $460,705 - $688,602	-27,293 Reduced 18.4%	121,056 $2.76 Million
Q2 2021 Aug 16, 2021	BUY	$15.9 - $21.15 $299,587 - $398,508	18,842 Added 14.55%	148,349 $2.8 Million
Q1 2021 May 17, 2021	SELL	$13.3 - $17.55 $101,811 - $134,345	-7,655 Reduced 5.58%	129,507 $1.98 Million
Q4 2020 Feb 16, 2021	SELL	$12.08 - $17.46 $513,460 - $742,137	-42,505 Reduced 23.66%	137,162 $1.94 Million
Q3 2020 Nov 16, 2020	BUY	$13.62 - $17.66 $314,553 - $407,857	23,095 Added 14.75%	179,667 $2.82 Million
Q2 2020 Aug 14, 2020	BUY	$13.04 - $23.23 $1.68 Million - $2.99 Million	128,522 Added 458.19%	156,572 $2.74 Million
Q1 2020 May 14, 2020	SELL	$11.52 - $26.46 $2,200 - $5,053	-191 Reduced 0.68%	28,050 $412,000
Q4 2019 Feb 14, 2020	SELL	$15.24 - $25.09 $4,556 - $7,501	-299 Reduced 1.05%	28,241 $709,000
Q3 2019 Nov 14, 2019	SELL	$14.91 - $25.01 $17,385 - $29,161	-1,166 Reduced 3.93%	28,540 $429,000
Q2 2019 Aug 15, 2019	BUY	$21.48 - $27.71 $638,084 - $823,153	29,706 New	29,706 $742,000

Others Institutions Holding CRNX

# of Institutions

240

Shares Held

79.5M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.94B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Crinetics Pharmaceuticals, Inc. Transaction History